Abstract:Objective: The estimand framework offers a structured approach to define the treatment effect to be estimated in a clinical study. Defining the estimand upfront helps formulating the research question and informs study design, data collection and statistical analysis methods. Since the Trials within Cohorts (TwiCs) design has unique characteristics, the objective of this study is to describe considerations and provide guidance for formulating estimands for TwiCs studies. Methods: The key attributes of an estimand are the target population, treatments that are compared, the endpoint, intercurrent events and their handling, and the population-level summary measure. The estimand framework was applied retrospectively to two TwiCs studies: the SPONGE and UMBRELLA Fit trial. The aim is to demonstrate how the estimand framework can be implemented in TwiCs studies, thereby focusing on considerations relevant for defining the estimand. Three estimands were defined for both studies. For the SPONGE trial, estimators were derived. Results: Intercurrent events considered to occur exclusively or more frequently in TwiCs studies compared to conventional randomized trials included intervention refusal after randomization, misalignment of timing of routine cohort measurements and the intervention period, and participants in the control arm initiating treatments similar to the studied intervention. Considerations for handling refusal after randomization related to decisions on whether the target population should include all eligible participants or the subpopulation that would accept (or undergo) the intervention when offered. Considerations for handling treatment initiation in the control arm and misalignments of timing related to decisions on whether such events should be considered part of treatment policy or whether interest is in a hypothetical scenario where such events do not occur. Conclusion: The TwiCs study design has unique features that pose specific considerations when formulating an estimand. The examples in this study can provide guidance in the definition of estimands in future TwiCs studies.

Broad versus narrow research questions in evidence synthesis: a parallel to (and plea for) estimands

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Estimands in Real-World Evidence Studies

Translating questions to estimands in randomized clinical trials with intercurrent events

Applying the estimands framework to non-inferiority trials: guidance on choice of hypothetical estimands for non-adherence and comparison of estimation methods

Estimands in Hematologic Oncology Trials

Synthesizing cross-design evidence and cross-format data using network meta-regression

Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies

Estimands in clinical trials of complex disease processes

Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

Application of estimand framework to the design and analysis of multi-regional clinical trials

Clinical trial emulation in nephrology

Response to discussant comments on "NMA, the first 20 years"

Target Trial Emulation: A Call for More Widespread Use

Reverse‐Bayes methods for evidence assessment and research synthesis

Twenty years of network meta‐analysis: Continuing controversies and recent developments

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework

A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints

Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation